linaclotide
Sign in to saveLinaclotide (sold under the brand name Linzess in the US and Mexico, and as Constella elsewhere) is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause. It has a black box warning about the risk of serious dehydration in children in the US; the most common adverse effects in others include diarrhea.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 451564024
- Drug.image
- Linaclotide structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 315
- Drug.caption
- Linaclotide structure. A 2D line-angle schematic of linaclotide (sequence CCEYCCNPACTGCY). The phenolic ring of terminal tyrosine (Y) is in the lower left corner. Exaggerated bond lengths emphasize 3 disulfide (-S—S-) bonds between 6 cysteines (C's).
- Drug.tradename
- Linzess
- Drug.MedlinePlus
- a613007
- Drug.DailyMedID
- Linaclotide
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- A06
- Drug.ATC_suffix
- AX04
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 851199-59-2
- Drug.PubChem
- 16158208
via Wikipedia infobox
Research
491 papers- Linaclotide.2006
- Linaclotide.2012
- Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.The lancet. Gastroenterology & hepatology · 2024
- Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm.BMC gastroenterology · 2024
- Linaclotide.2026
via PubMed
Article
8 sectionsContents
- Medical use
- Adverse effects
- Pharmacology
- Chemistry
- History
- Society and culture
- Economics
- References
Linaclotide (sold under the brand name Linzess in the US and Mexico, and as Constella elsewhere) is a drug used to treat irritable bowel syndrome with constipation and chronic constipation with no known cause. It has a black box warning about the risk of serious dehydration in children in the US; the most common adverse effects in others include diarrhea.
It is an oligopeptide agonist of guanylate cyclase 2C and remains in the GI tract after it is taken by mouth. It was approved in the US and the European Union in 2012.
Connections
Categories
Chemical articles having Jmol setChemical articles having Jmol set/NoneChemical pages without DrugBank identifierDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs acting on the gastrointestinal system and metabolismDrugs developed by AbbVieDrugs with non-standard legal statusECHA InfoCard ID from WikidataTetradecapeptides